Cell and Gene Therapies in $3.5M Study for Aging
A
Aubrey de Grey at Longevity Investors Conference 2024
Story of claim
A study led by Aubrey de Grey combines cell and gene therapies with a $3.5M budget to reverse aging. Existing interventions are utilized, focusing on rejuvenation rather than slowing aging.
- Goal: To rejuvenate individuals by reversing aging, not just slowing it down.
- Proof: Combines novel interventions that don't alter metabolism but aim to remove aging-related damage.
- Nuances:
- $3 million paid upfront
- Combining existing promising interventions
- Doesn't generate significant IP
- Impact on Life: Potential to significantly advance the field of anti-aging research.
Investments
- Price: $3.5 million
- Time: 18 months
- Effort: High due to complexity and scale of research.
Risks
Financial risk due to high upfront investment without guaranteed IP returns.
Get Started 🚀
- Secure funding for large-scale studies
- Combine existing cell and gene therapies
- Focus on interventions shown to remove aging damage
Brogevity AI can make mistakes. Check important info.